Search results
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
Zacks via Yahoo Finance· 6 days agoPfizer's (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory...
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
Zacks· 6 days agoFree Report) announced that a phase III study on its mini-dystrophin gene therapy fordadistrogene movaparvovec for treating Duchenne muscular dystrophy ...
Avidity Biosciences to Participate in Upcoming Investor Conference
KPVI· 5 days agoA live webcast of the event, up-to-date event details and an archived replay will be available on the "Events and Presentations" page in the "Investors" section of Avidity's website at https ...
Entrada Therapeutics (NASDAQ:TRDA) versus BioLineRx (NASDAQ:BLRX) Head to Head Comparison
ETF DAILY NEWS· 4 days agoBioLineRx (NASDAQ:BLRX – Get Free Report) and Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast ...
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
Zacks· 5 days agoAn FDA panel endorses Eli Lilly's (LLY) Alzheimer's disease drug, donanemab. Pfizer's (PFE) DMD study on investigational gene therapy fails.
Sarepta shares hold steady as competitor drug fails trial By Investing.com
Investing.com· 6 days agoOn Thursday, BMO Capital maintained a positive outlook on Sarepta Therapeutics (NASDAQ:SRPT),...
Pfizer’s gene therapy for a muscle-wasting disorder misses main goal of late-stage study
WSAU Wausau· 6 days ago(Reuters) - Pfizer said on Wednesday its experimental gene therapy for a type of muscle-wasting...
Perry para-athlete’s road to a second state shot put title aided by special chair constructed by...
The Argus-Press· 2 days agoRecently graduated Perry High School students, and throwers on the school's track and field team,...
Surfing stars on the Olympic Torch Relay in French Polynesia
Olympics.com· 5 days agoTo celebrate this exceptional day, 122 torchbearers took it in turns to carry the Olympic Torch,...
PepGen (NASDAQ:PEPG) Reaches New 1-Year High at $18.38
ETF DAILY NEWS· 5 days agoShares of PepGen Inc. (NASDAQ:PEPG – Get Free Report) reached a new 52-week high during trading on Wednesday . The stock traded as high as $18.38 and last traded at $18.11, with a volume of ...